Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23985340 | 0.82 | DRD2 (0.39) | DRD2HTR2AHRH1THRBGAA | |
| SCHEMBL18994366 | 0.80 | GLS (0.35) | DRD2HTR2AHRH1SLC6A4LMNA | |
| SCHEMBL12165181 | 0.79 | GAA (0.38) | DRD2HTR2AHRH1THRBGAA | |
| SCHEMBL21325428 | 0.78 | SLC6A2 (0.36) | KDM4ESLC6A2SLC6A4SLC6A3 | |
| SCHEMBL293669 | 0.77 | — | — | |
| SCHEMBL25679936 | 0.76 | DRD2 (0.37) | DRD2HTR2AHRH1THRBGAA | |
| SCHEMBL5632040 | 0.76 | POLB (0.39) | MAPTHTTNPSR1SMN1; SMN2KDM4E | |
| SCHEMBL18859417 | 0.76 | THRB (0.37) | DRD2HTR2AHRH1THRBGAA | |
| SCHEMBL10049904 | 0.75 | — | — | |
| SCHEMBL984869 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10669252-B2 | Benzazepine derivative, preparation method, pharmaceutical composition and use thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2020-06-02 | — | — | US | disclosed |
| WO-2020081856-A1 | INHIBITORS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-04-23 | — | — | WO | disclosed |
| US-20190152941-A1 | BENZAZEPINE DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2019-05-23 | — | — | US | disclosed |
| US-9682998-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682998-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160362421-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2016-12-15 | — | — | US | disclosed |
| US-9403782-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20160002220-A1 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2016-01-07 | — | — | US | disclosed |
| US-20160002220-A1 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2016-01-07 | — | — | US | disclosed |
| US-20150329558-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2015-11-19 | — | — | US | disclosed |
| US-8183257-B2 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2012-05-22 | — | — | US | disclosed |
| US-20120010192-A1 | Fused Heterocyclic Compounds as Ion Channel Modulators | GILEAD SCIENCES, INC. | 2012-01-12 | — | — | US | disclosed |
| US-20090124653-A1 | Muscarinic Acetylcholine Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-05-14 | — | — | US | disclosed |
| US-20090124653-A1 | Muscarinic Acetylcholine Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-05-14 | — | — | US | disclosed |
| US-7498440-B2 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2009-03-03 | — | — | US | disclosed |
| US-7488827-B2 | Muscle relaxants; respiratory system disorders; asthma;COPD; emphysema; bronchitis | GLAXO GROUP LIMITED (GB) | 2009-02-10 | — | — | US | disclosed |
| US-7488827-B2 | Muscle relaxants; respiratory system disorders; asthma;COPD; emphysema; bronchitis | GLAXO GROUP LIMITED (GB) | 2009-02-10 | — | — | US | disclosed |
| US-20070249664-A1 | Muscarinic Acetylcholine Receptor Antagonists | GLAXO GROUP LIMITED | 2007-10-25 | — | — | US | disclosed |
| US-20070249664-A1 | Muscarinic Acetylcholine Receptor Antagonists | GLAXO GROUP LIMITED | 2007-10-25 | — | — | US | disclosed |
| US-20070185155-A1 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249664-A1 | Muscarinic Acetylcholine Receptor Antagonists | CHRM3, CHRNG, CHRM2 | DRD2 546/4885HTR2A 298/4885HRH1 182/4885 |
| US-20090124653-A1 | Muscarinic Acetylcholine Receptor Antagonists | CHRM3, CHRNG, CHRM2 | DRD2 546/4885HTR2A 298/4885HRH1 182/4885 |
| US-20160002220-A1 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | CHRM3, CHRNG, CHRM2 | DRD2 505/4885HTR2A 269/4885HRH1 175/4885 |
| US-20120010192-A1 | Fused Heterocyclic Compounds as Ion Channel Modulators | KCNJ2, KCNH2, CACNA1E | DRD2 1296/4885HTR2A 739/4885HRH1 976/4885 |
| US-10669252-B2 | Benzazepine derivative, preparation method, pharmaceutical composition and use thereof | TLR8, TLR1, TLR5 | DRD2 873/4885HTR2A 692/4885HRH1 708/4885 |
| US-20160362421-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, CACNA1A, KCNH2 | DRD2 1383/4885HTR2A 590/4885HRH1 1350/4885 |
| US-20190152941-A1 | BENZAZEPINE DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | TLR8, TLR1, TLR5 | DRD2 873/4885HTR2A 692/4885HRH1 708/4885 |
| US-20150329558-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, CACNA1A, KCNH2 | DRD2 1383/4885HTR2A 590/4885HRH1 1350/4885 |
| US-20070185155-A1 | Muscarinic acetylcholine receptor antagonists | CHRM3, CHRNG, CHRM2 | DRD2 546/4885HTR2A 298/4885HRH1 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.